Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis.
Chitnis T, Foley J, Ionete C, El Ayoubi NK, Saxena S, Gaitan-Walsh P, Lokhande H, Paul A, Saleh F, Weiner H, Qureshi F, Becich MJ, da Costa FR, Gehman VM, Zhang F, Keshavan A, Jalaleddini K, Ghoreyshi A, Khoury SJ. Chitnis T, et al. Among authors: qureshi f. Clin Immunol. 2023 Aug;253:109688. doi: 10.1016/j.clim.2023.109688. Epub 2023 Jul 4. Clin Immunol. 2023. PMID: 37414379 Free article.
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis.
Chitnis T, Qureshi F, Gehman VM, Becich M, Bove R, Cree BAC, Gomez R, Hauser SL, Henry RG, Katrib A, Lokhande H, Paul A, Caillier SJ, Santaniello A, Sattarnezhad N, Saxena S, Weiner H, Yano H, Baranzini SE. Chitnis T, et al. Among authors: qureshi f. medRxiv [Preprint]. 2023 Jul 3:2023.06.28.23291157. doi: 10.1101/2023.06.28.23291157. medRxiv. 2023. PMID: 37461671 Free PMC article. Updated. Preprint.
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis.
Jalaleddini K, Jakimovski D, Keshavan A, McCurdy S, Leyden K, Qureshi F, Ghoreyshi A, Bergsland N, Dwyer MG, Ramanathan M, Weinstock-Guttman B, Benedict RH, Zivadinov R. Jalaleddini K, et al. Among authors: qureshi f. Ann Clin Transl Neurol. 2024 Mar;11(3):729-743. doi: 10.1002/acn3.51996. Epub 2024 Jan 17. Ann Clin Transl Neurol. 2024. PMID: 38234075 Free PMC article.
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Jalaleddini K, Bermel RA, Talente B, Weinstein D, Qureshi F, Rasmussen M, Menon S, Amarapala M, Jordan K, Ghoreyshi A, McCurdy S, Edgeworth M. Jalaleddini K, et al. Among authors: qureshi f. Mult Scler. 2024 Mar;30(3):432-442. doi: 10.1177/13524585241227372. Epub 2024 Feb 19. Mult Scler. 2024. PMID: 38374525
Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores.
Jakimovski D, Qureshi F, Ramanathan M, Keshavan A, Leyden K, Jalaleddini K, Ghoreyshi A, Dwyer MG, Bergsland N, Marr K, Weinstock-Guttman B, Zivadinov R. Jakimovski D, et al. Among authors: qureshi f. Mult Scler Relat Disord. 2024 May 15;87:105687. doi: 10.1016/j.msard.2024.105687. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38776599
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Oechtering J, Stein K, Schaedelin SA, Maceski AM, Orleth A, Meier S, Willemse E, Qureshi F, Heijnen I, Regeniter A, Derfuss T, Benkert P, D'Souza M, Limberg M, Fischer-Barnicol B, Achtnichts L, Mueller S, Salmen A, Lalive PH, Bridel C, Pot C, Du Pasquier RA, Gobbi C, Wiendl H, Granziera C, Kappos L, Trendelenburg M, Leppert D, Lunemann JD, Kuhle J; Swiss MS Cohort Study. Oechtering J, et al. Among authors: qureshi f. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200212. doi: 10.1212/NXI.0000000000200212. Epub 2024 Feb 14. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38354323 Free article.
545 results